NNP
LFCR icon

Nachman Norwood & Parrott’s Lifecore Biomedical LFCR Stock Holding History

Nachman Norwood & Parrott’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$2K – 682
2020
Q3 		$2K Buy
+200
New +$1.91K ﹤0.01% 1089

Other funds holding LFCR

LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Nachman Norwood & Parrott's LFCR Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Lifecore Biomedical (LFCR) in Q4 2020, closing a stake of 200 shares — an estimated $2K sold.

Nachman Norwood & Parrott first reported a position in LFCR in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 96 funds tracked by Wall St. Rank hold LFCR as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Lifecore Biomedical position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 200 Lifecore Biomedical shares in Q4 2020, an estimated $2K.
  • Nachman Norwood & Parrott first reported a position in Lifecore Biomedical in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Lifecore Biomedical position peaked at $2K in Q3 2020.
  • 96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.